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Abstract 
The gastrointestinal (GI) tract, the key interface between ingested nutrients and the 
body, plays a critical role in regulating energy homeostasis. Gut-derived signals 
convey information regarding incoming nutrients to the brain, initiating changes in 
eating behavior and energy expenditure, to maintain energy balance. Here we 
review hormonal, neural and nutrient signals emanating from the GI tract and 
evidence for their role in controlling feeding behavior. Mechanistic studies that have 
utilized pharmacological and/or transgenic approaches targeting an individual 
hormone/mediator have yielded somewhat disappointing bodyweight changes, 
often leading to the hormone/mediator in question being dismissed as a potential 
obesity therapy. However, the recent finding of sustained weight-reduction in 
response to systemic administration of a long-acting analog of the gut-hormone 
glucagon-like peptide-1 (GLP-1) highlights the therapeutic potential of gut-derived 
signals acting via non-physiological mechanisms. Thus, we also review therapeutics 
strategies being utilized or developed to leverage GI signals in order to treat obesity. 
 
 
Keywords (3-4) 
Enteroendocrine cells, obesity, gastrointestinal peptides 
Abbreviations used: Apo A-IV, Apolipoprotein A-IV; BA, bile acids; CB1R, cannabinoid 
receptor 1 receptor CB1R; CART, CCK, cholecystokinin; CCK-1R, CCK-1 receptor; CNS, central 
nervous system; DAG, des-acyl ghrelin; DIO, diet-induced obesity; DPP-4, dipeptidyl 
peptidase 4; EEC, Enteroendocrine cell; ENS, enteric nervous system; FFAR, free fatty acid 
receptor; FTO, fat mass and obesity-associated; fMRI, functional magnetic resonance 
imaging; GI, gastrointestinal tract; GIP, glucose-dependent insulinotropic polypeptide, GLP-1, 
glucagon-like peptide-1; GCGR, glucagon receptor; GOAT, ghrelin-O-acyl transferase; GN, 
guanylin; GUC2C, guanylate cyclase 2C; GPCR, G protein-coupled receptor; GSR1a, growth 
hormone secretagogue receptor type 1a; IP, intra-peritoneal; MC4R, melanocortin-4 
receptor; NT, neurotensin; OEA; oleoylethanolamide; OXM, oxyntomodulin; PP, pancreatic 
polypeptide; PYY, peptide YY; PWS, Prader-Willi syndrome, RYGB, Roux-en-Y gastric bypass; 
T1R, Taste receptor 1; T2R, Taste receptor 2; T2D, type 2 diabetes; SCFA, short chain fatty 
acid; UGN, uroguanylin; YR, neuropeptide Y receptor. 
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1.0 Introduction 
Multiple GI-derived signals including peptides/hormones that originate from 
intestinal epithelial cells, bile acids and molecules produced by the gut microbiota, 
together with neural signals convey information regarding incoming nutrients
1-3
. 
These gut-derived signals act to co-ordinate the various organs involved in digestion 
and provide the brain with key information regarding the energy content of ingested 
nutrients (Figure 1). The effectiveness of bariatric surgery in producing sustained 
weight-reduction and amelioration of obesity-associated co-morbidities, together 
with the recent positive GLP-1 analogues clinical trial data highlight the opportunity 
afforded by modulating GI signals to tackle the growing obesity epidemic
4-6
. This 
review highlights our current understanding of peptides/hormones and lipid 
mediators that emanate from the GI tract with a focus on their effects on 
modulating eating behavior and bodyweight. Attention is also given to the emerging 
evidence that vagal afferent neurons function as integrators of peripheral energy 
homeostatic signals
2
. Neuroendocrine signals from the liver and pancreas also 
contribute to energy homeostasis regulation. However, this review is limited to 
signals from the GI tract per se. Several GI-derived peptides are also synthesized 
within the brain where they act as neuromodulators and/or neurotransmitters. This 
adds a layer of complexity in terms of utilizing pharmacological and transgenic 
approaches to delineate the physiological role of GI-derived peptides alone. 
However, these central receptors can be targeted therapeutically to modulate 
bodyweight by systemic administration of supra-physiological hormone doses or 
receptor agonists e.g. GLP-1 receptor agonists
7
. Moreover, in light of the apparent 
multiplicity and in-built redundancy in the mechanisms involved in regulating energy 
homeostasis, therapeutic strategies are now moving away from a single-target 
approach towards combination therapies and these will also be discussed
8
.  
 
2.0 Enteroendocrine cells (EECs) 
The GI tract represents the largest endocrine organ in the body harboring EECs along 
its entirety. EECs are the primary sensors of ingested nutrients and synthesize and 
release an array of peptides and hormones that act as autocrine, paracrine or 
endocrine regulators of digestive function, glucose homeostasis and energy balance
9, 
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10
. Recent, transgenic advances have enabled the isolation and characterization of 
the previously enigmatic EECs. These studies have revealed the presence of a 
complex array of receptors and transporters that enable EECs to sense the luminal 
and lamina propria environments and position EECs as key integrators of metabolic 
and inflammatory signaling
9
. Moreover, recent evidence suggests that EECs interact 
directly with neurons via synapse-like structure named neuropods, further adding to 
their integrative role
11
. Classically, EECs have been characterized by their location 
within the GI tract and by the peptides that they produced (Table 1). However, this 
view has been challenged by the finding that EECs express a broad repertoire of 
peptide hormone precursors and that the number, density and secretory profile can 
be modified
12
. Table 2 summarizes the known gut peptides, evidence for their role in 
controlling food intake, regulating bodyweight and their therapeutic potential. 
Below we summarize our current understanding of the regulation of EEC secretion 
and also review in more detail the gut peptides/mediators cholecystokinin (CCK), 
GLP-1, oxyntomodulin (OXM), peptide YY (PYY), neurotensin (NT) and apolipoprotein 
A-IV (Apo A-IV). 
 
2.1 Cholecystokinin (CCK) 
CCK, the archetypal GI satiation peptide, first shown to acutely inhibit food intake 
over three decades ago
13
, is produced by I-cells in the duodenal and jejunal mucosa, 
in the enteric nervous system (ENS) and within the central nervous system (CNS). 
CCK mediates its biological effects via the CCK-1 receptor (CCK1R), which 
predominates in the periphery and CCK2R found mainly in the brain. Intestinal CCK 
secreted in response to luminal nutrients, in particular lipids and proteins, facilitates 
optimal digestion by stimulating the release of lipolytic and proteolytic enzymes 
from the gallbladder and pancreas regulating gastric emptying. Although CCK is 
released into the circulation, chemical and surgical ablation experiments have 
revealed that CCK’s anorectic effects are exerted via a paracrine mechanism 
involving CCK1R on vagal afferents that project to the nucleus tractus solitarus and 
then to the paraventricular nucleus
14, 15
. A physiological role for CCK1R in satiation is 
supported by the findings that rats-lacking CCK1R show increased meal size and 
gradually become obese
16
 and that CCK1R antagonist administration leads to 
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increased hunger and increased meal size in humans
17
. Despite these findings 
CCK1R-deficient mice have no bodyweight phenotype and chronic administration 
leaves bodyweight unaltered, due to a compensatory increase in meal frequency
18, 
19
. Furthermore, whilst potent receptor agonists have been developed, these have 
not reached clinical practice due to limited efficacy and side effects. However, it is 
now clear that CCK1R activation stimulates multiple interacting signaling cascades 
and hopefully biased agonists targeting the satiety effects alone will overcome 
previous problems
20
. An alternative approach is to use positive allosteric modulators 
without intrinsic agonist activity to enhance the satiety effect of nutrient-stimulated 
endogenous CCK
20
. Furthermore, given that CCK has been shown to interact 
synergistically with leptin, amylin and glucagon, combination therapies based upon 
these synergies are likely to be more effective than a single-agent approach. 
2.2 Proglucagon gene products:  
The proglucagon gene encodes pre-proglucagon which undergoes tissue specific 
post-translational processing to generate GLP-1, GLP-2, OXM, glucagon and 
glicentin
21
. Here we review the data pertaining to the effects of GLP-1 and OXM on 
energy intake and bodyweight. 
 
2.2.1 GLP-1 
GLP-1 is primarily expressed within L-cells of the GI tract and in the brainstem. L-cell 
derived GLP-1 is synthesized as GLP-11-37 and GLP-11-36 amide. These undergo N-
terminus cleavage to produce the biologically active fragments GLP-17-37 and GLP-17-
36 amide that bind to and activate the GLP-1 receptor (GLP-1R). In response to nutrient-
ingestion circulating GLP-1 concentrations show a biphasic response
22
: a rapid at 15-
30 minutes then a later peak at 60-90 minutes
21
. Nutrients entering the proximal GI 
tract are thought to trigger GLP-1 release from ileal L-cells by a neurohumoral reflex 
generating the early increase. However, GLP-1 expressing EECs have now been 
identified within the human proximal intestine
23
. Thus, direct EEC nutrient-sensing 
may contribute to the early GLP-1 rise, in addition to mediating the later increase in 
circulating GLP-1 levels. GLP-1 secretion is also modulated directly and indirectly by 
chemical, neural and humoral factors
9
. Once secreted, active GLP-1 is almost 
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immediately degraded by dipeptidyl peptidase-4 (DPP-4), consequently only 
approximately 25% reaches the hepatoportal circulation and less than 10% reaches 
the systemic circulation
21, 24
.  
 
The physiological role of GLP-1/GLP-1R in regulating glucose homeostasis is well 
established and therapies targeting the GLP-1/GLP-1R system are widely used to 
treat people with type 2 diabetes (T2D)
5
. In contrast, the physiological role of 
endogenous GLP-1 in regulating feeding behavior and bodyweight is less clear-cut. 
Whilst peripheral administration of GLP-1 or GLP-1R agonists reduce energy intake 
and chronic administration reduces bodyweight, GLP-1R deficient mice exhibit 
normal feeding behavior and bodyweight
25
. These findings suggest that the GLP-
1/GLP-1R system is not necessary for energy homeostasis. The anorectic effects of 
intra-peritoneal (IP) GLP-1 administration are abolished by vagotomy or capsaicin 
administration, implicating a paracrine mechanism action
26
. A paracrine mechanism 
of action is also in keeping with GLP-1’s short half-life, by the presence of GLP-1R on 
vagal afferents and the finding that IP GLP-1 administration leads to increased vagal 
firing
27
. In contrast, the anorectic effect of intravenous or subcutaneous GLP-1 is 
unaffected by vagotomy or capsaicin treatment, suggesting a direct effect via CNS 
GLP-1Rs. Moreover, comparative studies utilizing a long-acting GLP-1R agonist 
have confirmed a direct modulatory effect upon central appetite-regulating 
circuits. However, it is unlikely that endogenous GLP-1 circulating concentrations 
reach the levels required for a direct effect, albeit with the caveat of following 
bariatric procedures where L-cell stimulation is markedly enhanced
28
. Importantly, 
long-acting GLP-1R agonist administration has been shown to lead to sustained 
weight-reduction with amelioration of obesity-associated comorbidities
4
. These 
findings highlight that gut-derived signals working through non-physiological means 
represent attractive therapeutic strategies for obesity. 
 
2.2.2 OXM 
OXM is a 37-amino-acid peptide, containing the 29-amino-acid sequence of glucagon 
followed by an 8-amino-acid carboxy-terminal extension, activates GLP-1Rs and 
glucagon receptors (GCGR)
29
. Within the GI tract OXM is co-distributed, co-expressed 
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and co-secreted with GLP-1 and is also inactivated by DPP4
30
. Similar to GLP-1, OXM 
causes glucose-dependent insulin secretion and improves glucose tolerance in mice 
and humans with T2D despite acting as a GCGR agonist. Peripheral administration of 
OXM reduces energy intake in rodents
31
, lean
32
 and obese human subjects. 
Repeated subcutaneous administration of OXM to overweight/obese people reduces 
energy intake, increases energy expenditure and leads to weight loss
33, 34
.  Studies on 
glp-1r null and GCRG-null mice have identified that the anorectic effects of OXM 
require the GLP-1R and are thought to involve both vagal and direct CNS activation
35
. 
While stimulatory effects of OXM on energy expenditure are mediated by the GCGR. 
However, despite mediating its anorectic effects via the GLP-1R, peripheral 
administered OXM and GLP-1 produce differential c-fos activation patterns within 
the hypothalamus suggesting differential mechanisms of action
36
 and implies the 
presence of an as yet to be identified OXM receptor. Overall OXM represents a 
promising weight-loss therapy that appears well tolerated in humans. However, its 
clinical utility is limited by its short half-life.  Thus OXM analogues and modified OXM 
molecules with altered GLP-1 receptor binding affinity and increased duration of 
action in vivo have been developed and tested as a proof-of-concept while several 
others are currently being actively investigated by the pharmaceutical industry
37
. 
 
2.3 Peptide YY 
Peptide YY together with neuropeptide Y (NPY) and pancreatic polypeptide (PP) 
belong to the PP-fold family and mediate their effects via Y-receptors (YR) that 
belong to G-protein-coupled receptor (GPCR) superfamily
38
. PYY is expressed within 
GI EECs, the pancreas and brainstem neurons. PYY is a 36-amino-acid peptide (PYY1-
36) often described as a distal GI tract hormone due to its predominance within L-
cells of the ileum and colon. However, this classical view has been debunked by the 
finding of PYY expression within the stomach, duodenum and jejunum together with 
the newfound ability of EECs to adapt their secretory profile. It is also now clear that 
in addition to being co-secreted with GLP-1, other gut peptides such as CCK, secretin, 
glucose-dependent insulinotropic polypeptide (GIP) and neurotensin (NT) may be co-
secreted with PYY. Circulating PYY levels are low and progressively decrease in the 
fasted state. In response to nutrient-ingestion, PYY levels rapidly increase to reach a 
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plateau at 60-90 minutes and then remain elevated for several hours post-ingestion 
with caloric content and macronutrient composition impacting upon secretion
38
. 
PYY3-36, produced by N-terminal cleavage of PYY1-36 via DPP4, is the main 
circulating form. Importantly, PYY1-36 and PYY3-36 exhibit divergent effects on 
feeding behavior as a consequence of differential YR affinities. PYY1-36 has 
equivalent affinities for the Y1R and Y2R and increases food intake when 
administered centrally, whereas PYY3-36 is a high-affinity ligand for the Y2R and 
reduces energy intake when administered peripherally. Studies y2r-null mice 
coupled with pharmacological approaches using a selective Y2R antagonist have 
identified a crucial role for the Y2R in mediating the anorectic effects of PYY3-36
39
. A 
physiological role for PYY3-36 in bodyweight regulation is suggested by the finding 
that PYY-null mice are hyperphagic and obese and that PYY3-36 replacement 
reverses their obese phenotype
40
. Translational studies indicate that PYY3-36 
mediates its anorectic effects predominantly by acting upon central appetite-
regulating circuits with the hypothalamic arcuate nucleus and brainstem regions. 
Y2Rs are present on vagal afferents and vagal firing is increased in response to IP 
PYY3-36 suggesting a paracrine mechanism of action. However, evidence suggests 
that the main anorectic effect of PYY3-36 is mediated by a direct effect upon central 
appetite-regulating circuits. Importantly, human brain functional magnetic 
resonance imaging (fMRI) studies revealed that peripheral PYY3-36 administration 
altered neural activity within homeostatic, reward and polymodal brain regions
41
. 
PYY3-36 was the first gut hormone shown to regulate homeostatic and hedonic brain 
circuits in humans. However, subsequently additional gut hormones and gut-derived 
signals have also been shown to act in this manner. More recently PYY3-36 has been 
shown to have beneficial effects upon glucose homeostasis and has been implicated 
in contributing to the immediate glycemic improvements observed following 
bariatric surgery
38, 42
. Taken together, PYY3-36/Y2R system represents an attractive 
therapeutic target for treating obesity and T2D. However, whilst acute PYY3-36 
administration to people with overweight and obesity led to a marked reduction in 
24-hour energy intake, effective, safe PYY3-36/Y2 agonists have yet to reach the 
clinical arena. Studies combining PYY3-36 administration with other gut peptides 
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have revealed synergistic anorectic effects and suggest that Y2R agonist in 
combination with other gut peptides are likely to offer increased efficacy. 
 
2.4 Neurotensin (NT)  
NT is a 13 amino-acid peptide expressed in the CNS
43
 and GI tract EECs
44
. NT exerts 
its pleiotropic biological actions via three NT receptors; NTR1, NTR2, and NTR3, that 
are widely distributed with the brain and peripherally. Central NT administration 
reduces energy intake via the NTR1
45
 and is implicated in controlling food reward 
interacting with the dopaminergic system and leptin
46
. GI NT is released in response 
to nutrient-ingestion, in particular to fat, and regulates GI motility, pancreatic and 
biliary secretion, facilitates fat translocation and acts as an incretin. Circulating NT 
has a very short half-life of around 30 seconds
47
. Peripheral administration of NT 
causes a transient reduction in energy intake
48
, an effect that is blocked by NT1R 
antagonist administration
49
. Systemic administration of PEGylated NT, with an 
increased half-life causes a sustained reduction in food intake coupled with 
increased hypothalamic POMC expression
49
. Studies examining the impact of 
vagotomy on the anorectic effect of peripherally administered NT suggest that NT 
acts via both endocrine and paracrine mechanisms with high circulating NT levels 
directly accessing CNS appetite-regulatory circuits and paracrine vagal mechanisms 
mediating the anorectic effect when circulating NT levels are low. Recent studies 
have revealed that within the GI tract NT, PYY and GLP-1 are not only co-expressed 
but also co-secreted in response to a wide range of stimuli including bile acids (BA)
50
. 
Moreover, NT has been shown to acts synergistically with GLP-1 and PYY when 
administered peripherally. In addition, circulating NT concentrations are increased 
following bariatric procedures that increase EEC exposure to nutrients
51
. 
Furthermore, administration of an NTR1 antagonist to rats following Roux-en-Y 
gastric bypass (RYGB) was associated with increased food intake, suggesting that 
circulating NT post-RYGB contributes to reduced energy intake
49
. Taken together 
these findings suggest that peripheral administration of long-acting NT or NTR1 
agonists might be beneficial for weight-reduction. However, the widespread 
distribution of NTR1, NTR2 and NTR3 and the pleiotropic effects of NT including 
cardiovascular effects may limit its therapeutic potential as an obesity therapy. 
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Moreover, the recent finding that NT-deficient mice exhibit reduced intestinal fat 
absorption and are protected against diet-induced obesity (DIO) despite having a 
similar feeding behaviour and energy expenditure compared to their wild-type 
littermates further complicates the picture
52
.  
 
2.5 Ghrelin 
Ghrelin, a 28-amino-acid peptide hormone
53
, is secreted from P/D1-type cells in 
humans, X/A like-type cells in rodents, which are a distinct population of endocrine 
cells located within the gastric oxyntic mucosa
54
. Ghrelin-producing cells are also 
present throughout the small intestine with the greatest numbers in the duodenum. 
Of note, majority of the proximal P/D1-type cells are closed-type and thus not 
regulated directly by the stomach luminal contents. In contrast, ghrelin-producing 
cells in the duodenum and jejunum are open-type
55
. Circulating ghrelin levels 
increase before spontaneously initiated meals and fall rapidly after nutrient-
ingestion in proportion to the energy intake through as yet poorly characterized 
mechanism
56, 57
. In vivo and in vitro studies have shown that epinephrine, 
norepinephrine, endothelin and secretin increase ghrelin release, whereas 
hyperglycemia, insulin, gastrin releasing peptide, PYY3-36, OXM, GLP-1, CCK, GIP and 
somatostatin decrease ghrelin release. However, it remains unclear whether these 
factors act directly on ghrelin cells or indirectly via neighboring cells and for many 
the physiological relevance to be determined
55
. 
 
In order to bind to its only known receptor, the growth hormone secretagogue 
receptor type 1a (GSR1a), ghrelin requires attachment of a fatty acid side chain to its 
serine-3 residue. This post-translation acylation is mediated by ghrelin O-acyl-
transferase (GOAT)
58
. Acyl-ghrelin is absent in GOAT null mice indicating that GOAT 
is the only enzyme capable of activating ghrelin in vivo. In rodents, peripheral acyl-
ghrelin administration increases energy intake and repeated administration results 
in increased adiposity. Similarly in humans, peripheral acyl-ghrelin administration 
increases hunger and energy intake in lean, obese, healthy and malnourished 
individuals
59, 60
. The orexigenic effect of ghrelin is specifically modulated through 
GHSR1a, as ghrelin fails to promote food intake in GHSR1a-null mice
61
. Ghrelin acts 
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directly upon CNS appetite-regulating circuits, in particular the arcuate nucleus of 
the hypothalamus
62
 and also indirectly via the vagus
63
. Acyl-ghrelin administration 
shifts the food preference toward fat-rich diets and leads to increased consumption 
of palatable saccharin solution
64
. Ghrelin-null and GOAT-null mice are 
indistinguishable from wild-type mice when fed normal chow
55
, however, they are 
protected from DIO
65
 and display reduced hedonic feeding. Together these data 
suggest that ghrelin’s main feeding effect is on ‘reward based/hedonic’ feeding. 
Furthermore, ghrelin administration to human subjects during fMRI brain scanning 
increases the neural response to food pictures in several brain regions implicated in 
hedonic feeding
55
. More recently, attenuated post-meal acyl-ghrelin suppression and 
altered CNS responsivity to circulating acyl-ghrelin have been implicated as drivers of 
the increased appetite and hedonic food preferences observed in people 
homozygous for the obesity-risk A-allele of the fat mass and obesity-associated gene 
(FTO) linked single nucleotide polymorphism rs9939609
66
. Moreover, an increased 
circulating acyl-ghrelin levels in response to dietary restriction seems to play a 
causative role in weight regain and recidivism after diet-induced weight loss
67
 and in 
patients with Prader-Willi syndrome (PWS), in whom high ghrelin levels are 
suggested to cause hyperphagia and weight gain
68
. In light of the weight-promoting 
effects of acyl-ghrelin, a novel ghrelin-receptor agonist anamorelin, is being trialled 
to assess the safety and effectiveness for the treatment of patients with cancer 
anorexia and cachexia
69
.  
 
Des-acyl ghrelin (DAG) represent approximately 80% of circulating ghrelin and was 
initially viewed purely as an acyl-ghrelin degradation product
70
. However, emerging 
evidence suggests that DAG has opposing biological actions to acyl-ghrelin and 
moreover that the ratio of acyl-ghrelin to DAG (acyl-ghrelin/DAG) is important. In 
support of this hypothesis, in patient patients with PWS, hyperphagia and weight 
gain has been shown to coincide with an increase in acyl-ghrelin/DAG
71
. 
Furthermore, a stabilized DAG peptide analog, AZP-531, has been designed and is 
being tested for the treatment of PWS and for common obesity. Other approaches 
include GOAT inhibition, ghrelin receptor antagonists and immune mediated ghrelin 
inactivation
72, 73
. 
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2.6 Nesfatin-1 
In 2006, centrally produced nesfatin-1 was identified as an anorexigenic peptide and 
suggested to be a physiological regulator of energy balance on the basis that 
reduced nesfatin-1 signalling increased feeding
74
. Nesfatin-1, derived from a 
precursor peptide NEFA/nucleobindin-2, is widely expressed within the CNS and 
periphery where it exerts pleiotropic effects including influencing digestive function, 
glucose homeostasis, sleep and anxiety
75
. However, the corresponding receptor(s) 
remain to be identified. Within the periphery the stomach exhibits the highest 
nesfatin-1 expression levels and here nesfatin-1 is co-expressed with ghrelin within 
P/D1 cells, though stored within different vesicles
76
.  Circulating nesfatin-1 levels are 
low in the fasted state and increase with feeding suggesting that peripheral nesfatin-
1 might also regulate feeding behaviour acting through autocrine, paracrine and/or 
endocrine routes. However, the effect of peripheral nesfatin-1 administration upon 
feeding behaviour has yielded mixed findings. Thus the role of peripheral and in 
particular gastric nesfatin-1 remains to be determined
77
. Nevertheless, nesfatin-1 
still represents a potential therapeutic target to treat people with obesity in light of 
its beneficial metabolic effects when administered centrally and the finding that 
peripheral nesfatin-1 can cross the blood brain barrier.  
 
2.7 Gastric leptin 
Leptin is expressed in, and secreted by gastric chief cells and gastric endocrine P-
cells, into the gastric lumen
78,79
. Gastric leptin is implicated in the short-term 
regulation of food intake and is rapidly secreted in response to food intake and 
peptide hormones, such as CCK and insulin, a mechanism that is vagally mediated
80
. 
Leptin receptors are present on gastric vagal afferents and interestingly studies have 
shown that the response of vagal gastric afferents to leptin is dynamic and 
dependent on nutritional status. In the fasted state or following 12-weeks 
consumption of high-fat diet, gastric leptin inhibits gastric tension sensitive vagal 
afferents, facilitating increased food intake. In contrast, in the fed state gastric leptin 
has an excitatory effect on gastric vagal afferents
81
. 
Gastric leptin is secreted bound to a soluble leptin receptor that protects it from 
proteolysis. Upon reaching the duodenum, it attaches to a duodenal enterocyte 
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transmembrane leptin receptor and is transcytosed to the luminal basal membrane 
and absorbed into the circulation, impacting upon energy homeostasis through 
paracrine and endocrine mechanisms
79
.  
 
2.8 Regulation of EEC secretion and nutrient-sensing 
A combination of nutrient, neural and hormonal pathways regulate expression and 
secretion of gut peptides from EECs
82
. Moreover, EECs are influenced by diet, 
microbiota, inflammation and host genetic factors. Of particular note, in light of the 
prevalence of genetic variation within the melanocortin-4 receptor (MC4R), is the 
finding MC4R are present on EECs where they regulate the secretion of PYY and 
ghrelin
83
. EECs detect an array of luminal nutrient stimuli via through GPCRs, ion and 
solute transporters, intra-cellular metabolism, which lead to calcium influx and gut 
peptide release into the subcellular space. Luminal stimuli include sweet and bitter 
tastants, monosaccharides, free fatty acids, monacylglycerols, amino acids, 
di/tripeptides, indole and short-chain fatty acids (SCFA). EECs also sense a number of 
non-nutrient and luminal paracrine signals including cytokines, BA, gut hormones 
and enteric neurotransmitters. Endocrine and paracrine signals acting via surface 
receptors on the basolateral surface of neighboring enterocytes and/or other EECs 
modulate EEC function. BAs act as non-nutrient stimuli of L-cells via activating TGR5 
leading to release of L-cell gut peptides
84
. In humans, administration of BAs has been 
associated with increased plasma GLP-1 levels and improved glucose homeostasis.  
 
Targeting secretion of EECs in order to recapitulate the gut peptide milieu following 
gastric bypass surgery represents an attractive therapeutic strategy for the 
treatment of obesity. Indeed, evidence suggests that altered EEC secretion as a 
consequence of altered nutrient stimulation contributes to the weight-loss and 
metabolic benefits of bariatric surgery
85
. Similarly, preventing nutrient contact with 
the duodenal mucosa by placing an endoscopic liner known as Endobarrier
86
,  or 
thermic ablation of the duodenal mucosa
87
, results in improved metabolic profiles 
hypothetically based on their impact upon EEC functioning. Given the rapid recent 
advancement in our understanding of EEC biology functional foods or designer drugs 
aimed at modulating EEC secretion will soon reach clinical practice. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
 
2.9 Taste receptors 
Taste receptors that respond to sweet, bitter and umami stimuli, together with their 
associated G-proteins have been identified within the GI mucosa co-localized with 
several gut peptides including ghrelin GLP-1, GIP, and CCK
88,89
. Sweet, umami and 
bitter-tasting stimuli are detected by members of two GPCR families, the taste 1 
receptor (T1R) and taste 2-receptor family (T2R). Subtypes of T1R heterodimerize to 
detect sweet tastants (T1R2 and T1R3) and umami tastants (T1R1 and T1R3), while 
the T2R receptor family members can detect bitter stimuli. 
 
In vitro and in vivo studies suggest that taste receptors may play a functional role in 
detecting luminal nutrients with subsequent modulation of hormonal or neural 
signaling engendering downstream effects of glucose and energy homeostasis
90
. For 
example, gustducin-coupled sweet taste receptors, which sense glucose and artificial 
sweetners, have been shown to be co-localized in L-cells and mice-lacking alpha-
gustducin exhibit an attenuated GLP-1 and insulin release in response to enteral 
glucose
91
. These findings suggest a functional role for the sweet taste receptor in 
modulating GLP-1 release.  However, the finding artificial sweetners fail to increase 
GLP-1
92-94
 calls into question the functional role of sweet taste receptors in modulate 
GLP-1 secretion
95
. Whilst the precise role of taste receptors within the GI mucosa 
remains to be determined they offer a potential mechanisms for modulating EEC 
secretion.  
 
3.0 Additional GI epithelium derived signals 
3.1 Apolipoprotein A-IV (Apo A-IV)   
Apo A-IV is a glycoprotein produced within enterocytes of the small intestine, the 
hypothalamus and in rodents, within the liver. Intestinal Apo A-IV is synthesized and 
secreted in response to the absorption and uptake of long-chain fatty acid into 
chylomicrons. Neither medium-chain fatty acids nor SCFA impact upon its secretion.  
In response to lipid ingestion circulating Apo-AIV levels increase within 15 minutes 
and remain elevated until 30 minutes post-meal
96
. This finding coupled with the fact 
that Apo A-IV infusion that reproduces post-meal circulating levels, dose-
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dependently inhibits food intake has led to Apo A-IV being proposed as a short-term 
satiety signal
97
.  A role for CNS sites as mediators of the anorectic effects of Apo A-IV 
is supported by studies showing a reduction in feeding with central Apo A-IV 
injection and increased food intake with central administration of Apo A-IV 
neutralising antibodies. However, these studies are unable to differentiate the 
relative contribution of GI-derived Apo A-IV compared to centrally released Apo A-IV 
in mediating the anorectic effects of Apo A-IV. Vagotomy abolishes the anorectic 
actions of Apo A-IV suggesting a key role for vagal afferents
98
.   
 
Evidence for cross-talk between CCK and Apo A-IV is suggested by the following 
observations: CCK and Apo A-IV secretion are both dependent upon chylomicron 
formation; Apo A-IV increases CCK-elicited vagal firing: Apo A-IV induced satiation 
requires an intact CCK system including vagal afferent CCK-1R; the anorectic action 
of CCK is increased in Apo A-IV null mice; CCK and Apo A-IV act synergistically to 
reduce food intake. Taken together these findings suggest that CCK and Apo A-IV 
work co-dependently to reduce food intake. In addition to modulating food intake, 
Apo A-IV has beneficial glycemic effects and has been shown to act as an incretin but 
with a substantially longer half-life than GLP-1 or GIP
96
.  Thus, Apo A-IV represents a 
potential therapeutic target either alone or in combination. However, despite the 
marked advances in our understanding of the biological roles of Apo A-IV the 
receptor(s) through which it mediates its effects remain to be identified. 
  
3.2 Guanylin and Uroguanylin 
Guanylin/guanylate cyclase activator 2A (GN/GUCA2A) and uroguanylin/guanylate 
cyclase activator 2B (UGN/ GUCA2B) were identified in 1992
99
 and 1993
100
 
respectively during a search for endogenous ligands for intestinal guanylate cyclase 
2C (GUCY2C), a transmembrane receptor that had been identified as the target of 
diarrheagenic bacterial heat-stable endotoxins. GN and UGN are secreted as 
prohormones; proguanylin and proUGN, and undergo proteolytic cleavage to 
generate c-terminal active peptides GN and UGN. The guanylate peptide family not 
only regulate fluid and electrolyte balance but also epithelial cell homeostatic 
programs in the gut with GUCY2C being implicated as a tumor suppressor that can 
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potentially be targeted for tumor chemoprevention. Within the GI tract, GN 
increases in the cranio-caudal direction whilst UGN decrease, however the cellular 
sources are debated and include goblet cells, entero-/colonocytes, EECs and tuft 
cells
101
. 
 
In addition to their paracrine actions pro-UGN and pro-GN are secreted into the 
circulation where they can act in an endocrine manner. Circulating pro-UGN and pro-
GN levels are nutritionally regulated being low in fasted state and increasing with 
feeding. Moreover, UGN levels are regulated in a leptin-dependent manner
102
. UGN 
was first suggested to regulate energy balance by Vallentino et al., who reported 
that pro-UGN is cleaved within the hypothalamus to generate UGN, which activates 
GUCY2C in hypothalamic neurons and anorexigenic pathways
103
. They also reported 
that GUCY2C null mice were hyperphagic with increased bodyweight that was 
exacerbated by high-fat feeding 
103
. However, another group were unable to elicit an 
anorectic effect of central UGN or GUCY2C receptor agonist and reported that 
GUCY2C null mice only exhibited a modest increase in body weight, adiposity and 
glucose intolerance when exposed to high-fat diet (HFD)
104
.  
 
Recently, adipose tissue has been identified as a target for the guanylin system with 
GN and UGN stimulating lipolysis
105
. Moreover, Folguiera and colleagues have 
reported that chronic central UGN administration reduced weight gain and adiposity 
in DIO mice. However, these effects were independent of changes in food intake and 
were due to increased brown adipose tissue thermogenesis, browning of white 
adipose tissue together with increased lipolysis due to sympathetic nervous system 
activation. In addition, increased fecal output was noted due to parasympathetic 
activation
102
. Whilst many questions remain to be addressed the guanylate system 
still holds promise as a potential therapeutic target. 
 
3.3 Intestinal lipid-derived signals that sense dietary fat 
3.3.1 Lipid-derived orexigenic endocannabinoid messengers  
The presence of oral long chain unsaturated fatty acids in the mouth has been 
reported to lead to increased production of lipid-derived endocannabinoid 
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messengers such as anadamide that are high affinity agonists for the cannabinoid 
receptors CB1 and CB2. Activation of the CB1 receptor (CB1R), which expressed 
centrally and peripherally, stimulates food intake whilst CB1 receptor blockade 
reduces feeding. The mechanisms by which CB1R activation increases food intake 
are unclear but they do not require the vagus
106
. Similarly, the chemical source of fat 
taste and the receptor(s) mediating fat detection remain to be determined. 
However, release of non-esterified fatty acids from triacylglycerols is required in 
order for fat to be detected. Studies in genetically modified mice had implicated 
CD36, GPR40, GP120 and TRPM5 in fat sensing
107
. However, more recent data 
question that role of GPR40 and GPR120 in fat ‘taste’
108
.  
 
3.3.2 Anorexic lipid mediators 
As fat enters the small intestine oleic acid liberated from the digestion of 
triacylglycerols is captured by the epithelial lining and converted into the anorexic 
lipid mediator oleoylethanolamide (OEA). OEA leads to reduced food intake, 
increased fatty acid absorption from the small intestine and stimulates lipolysis. OEA 
is increased in the duodenal and jejunum only not in the circulation suggesting a 
paracrine mechanism of action. OEA also binds to GPR119 on L-cells stimulating 
secretion of L-cell products. The mechanisms by which OEA promotes satiety remain 
unclear but require PPAR alpha-receptor
109
. OEA-induced satiety is described as 
being abolished by vagotomy
81
 and capsaicin treatment
110
, but a subsequent paper 
reported that selective afferent vagotomy did not block feeding inhibition
111
.  
 
3.4 Appetition 
Studies report that the presence of dietary sugar or fat in the gut can generate post-
oral signals that lead to conditioned food preferences and stimulation of appetite 
and energy intake, a process termed “appetition” by Sclafani and colleagues
112
. 
Recent data suggest that SGLT1 functions as an intestinal sugar sensor that promotes 
the appetite for glucose-rich foods. However, the identity of the appetition signal 
generated by SGLT1 remains to be identiﬁed
113
. Moreover, studies in mice 
undergoing bariatric surgery suggest that sugar sensing in the duodenum plays a key 
role in mediating dorsal striatal dopamine release in response to sugar ingestion 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18
which is necessary for sweet appetite conditioning
114
. Studies utilizing transgenic 
mice suggest that intestinal GPR40 and GPR120 fatty acid sensors have critical roles 
in post-oral intake stimulation and preference conditioning by dietary fat
115
. The 
mechanisms underlying appetition are still being investigated but may involve other 
non-dopaminergic neurochemical systems and/or presently undiscovered hormonal 
mediators released from the gut mucosa. A greater understanding of the relative 
importance of post-oral appetition in humans and the underlying mechanisms is 
warranted. 
 
4.0 Neural Signals 
4.1 Vagal afferent neurons as early integrators of peripheral energy signals 
It is now apparent that vagal afferent firing is influenced by leptin, a wide range of 
gut hormones, gut-derived lipid mediators, shifts in gut microbiota and gut 
inflammation. Moreover, rodent studies show that vagal afferent neurons exhibit 
plasticity in terms of their receptor and neuropeptide expression that is regulated by 
nutrient status. For example, fasting for a few hours reduces expression of Y2R and 
anorectic cocaine amphetamine related-transcript but increases expression of CB1R 
and orexigenic melanin concentrating hormone, promoting orexigenic signaling. 
These changes are normally rapidly reversed to favor anorexigenic signaling upon re-
feeding
3
. A role for CCK in mediating this switch is suggested by the finding that 
CCK1R antagonism prevents this fast/fed vagal afferent neurochemical phenotype 
switch. More importantly, this fast/fed switch is impacted by obesity, inflammation 
and infections. For examples, in DIO animals vagal afferent sensitivity to anorectic 
and GI distention signals is reduced whilst sensitivity to ghrelin is increased. These 
changes are accompanied by a loss of this switching of vagal afferent phenotype in 
response to feeding with vagal afferents locked in a fasted state phenotype
3
. These 
findings highlight the role of vagal afferents act as early integrators peripheral 
energy signals. 
 
4.2 Enteric Nervous System 
The enteric nervous system (ENS) is a network of nerve fibers and ganglia that 
innervates the intestine and interacts with sympathetic and parasympathetic 
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nervous system and utilizes a wide variety of peptide neurotransmitters in addition 
to acetylcholine and noradrenaline
10
. Gut hormone secretion is modulated by signals 
from other EEC populations and from the ENS. Enteric neurons are also capable of 
sensing certain absorbed nutrients directly. For example, subsets of enteric neurons 
express the SCFA receptor FFAR3. In turn, the ENS fine-tunes the function of EECs.  
 
5.0 Microbiota 
The role of the gut microbiota is covered by Nieuwdorp and colleagues, in this issue, 
thus here we provide only a brief overview. The gut microbiota release and interact 
with an array of metabolites that can impact upon EEC secretion or directly influence 
energy regulation. For example, SCFA including acetate, butyrate and propionate are 
derived from microbial fermentation of non-digestable carbohydrate
82
. SCFA are 
ligands for two GPCRs, free fatty acid receptor 2 (FFAR2) and FFAR3 expressed in the 
in the GI tract. FFAR2 is present on L-cell and P/D1 cells and FFAR2 activation 
increases GLP-1 secretion and reduces ghrelin secretion. SCFA, given both orally or 
directly into the intestine reduce food intake and body weight in diabetic and 
healthy rodents and humans
1
.  
 
6.0 Inflammation 
Obesity is associated with a mild inflammatory state with increased intestinal 
permeability to bacterial lipopolysaccharide. This binds to toll-like receptor-4 on 
vagal afferent neurons leading to increased expression of the suppressor of cytokine 
signaling and attenuates the ability of leptin to activate vagal afferent neurons. This 
in turn impacts upon CCK signaling
1
.  
 
7.0 Leveraging GI signals to treat obesity and metabolic disorders 
Given the multiplicity, redundancy in, and compensatory capacity of, the 
mechanisms involved in regulating appetite and energy homeostasis, strategies to 
treat obesity are now focused upon targeting multiple systems. As discussed in 
Section 2.7, targeting EECs to release multiple endogenous is an attractive strategy. 
Alternative approaches that are being trialed include is exogenous administration of 
combined therapies and monomeric peptides co- and tri-agonists combinations of 
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endogenous peptides into a single molecule with receptor occupancy patterns that 
more closely resemble physiological regulation. For example GLP-1/GIP dual 
agonist
116
 GLP-1/GCG dual-agonist and tri-agonist GLP-1/GIP/GCG
8
. 
 
8.0 Conclusions and Future Perspectives 
Over the last decade our understanding of the elegant interrelated mechanisms by 
which GI-derived signals regulate food intake and bodyweight has markedly 
increased informing the rationale development of anti-obesity strategies. In 
addition, the long-acting GLP-1R analogue, liraglutide has become accepted as a 
therapeutic option for managing T2D and obesity, albeit acting through non-
physiological mechanisms. The redundancy and compensatory capacity of the 
mechanisms that govern energy balance are now recognized, leading to a new focus 
of therapeutic strategies that influence multiple systems. Despite the marked recent 
advances in our understanding of GI-derived energy signals many questions remain 
unanswered and additional research is needed in order for their full therapeutic 
potential to be leveraged. It is also clear that weight-loss response and weight-loss 
maintenance is highly variable in response to lifestyle interventions, 
pharmacotherapies and bariatric surgery. Thus in addition to the development of 
new therapeutic strategies we also need to develop more sophisticated phenotyping 
protocols for people with overweight and obesity in order to identify specific 
subpopulations and enable the development of precision medicine based 
approaches. 
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Table 1: Enteroendocrine cell types (EEC), peptide(s)/hormone(s) secreted, 
predominant location and proposed physiological role of peptide(s)/hormone(s)  
 
Cell 
type 
Hormone(s) Predominant 
location 
Function 
X/A* 
P/D1** 
Ghrelin, nesfatin-1 Gastric oxyntic 
mucosa and proximal 
small intestine 
Appetite control, food intake, 
glucose homeostasis, growth 
hormone release, sleep and mood 
Chief 
Cells 
P Cells 
Gastric leptin Gastric mucosa Short-term regulation of food 
intake 
D Somatostatin Stomach, small 
intestine 
Gastrointestinal hormone 
inhibition 
I CCK Duodenum, proximal 
jejunal mucosa, 
enteric nervous 
system 
Stimulates gallbladder contraction, 
inhibits stomach emptying and 
food intake 
K GIP Proximal small 
intestine 
Insulin release, gastric acid 
secretion,  
L GLP-1, GLP-2, PYY, 
oxyntomodulin, 
neurotensin 
Along the entire small 
intestine with ileal 
and colonic 
predominance 
Nutrient sensing, GI motility, 
stimulation of insulin release, 
inhibition of glucagon release, 
appetite suppression and 
promotion of energy expenditure. 
*Rodents; **Humans 
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Table 2: Enteroendocrine Cell Nutrient-Sensing Mechanisms 
Carbohydrate sensing 
Nutrient  Receptor activated Secreted peptide 
Glucose T1R2/T1R3 sweet taste 
receptor 
GLP-1 
Glucose 
α-methylglucopyranoside 
SGLT1 GLP-1 
GIP 
Glucose kATP Role unclear, may stimulate 
GLP-1 release 
Protein sensing 
Nutrient  Receptor activated Secreted peptide 
Peptones 
(via PEPT1) 
GPR93 CCK 
GLP-1 
L amino-acids CaSR CCK 
PYY 
L amino-acids GPR6a GLP-1 
L-glutamine 
L-aspartate 
T1R1/T1R3 umami taste 
receptor 
GLP-1 
Glutamate mGluR4 glutamate 
receptor 
GLP-1 
Lipid sensing 
Nutrient  Receptor activated Secreted peptide 
Endogenous saturated fatty 
acids (ethanolamides) 
GPR 119 GLP-1 
Glucose-dependent insulin 
secretion 
Short chain fatty acids FFAR2 PYY 
GLP-1 
Short chain fatty acids FFAR3  PYY 
Medium & long chain fatty 
acids 
FFAR1  GLP-1 
CCK 
GIP 
Medium & long chain fatty 
acids 
FFAR4  GLP-1 
GIP 
Medium & long chain fatty 
acids 
CD36 CCK 
Secretin 
 
Summary of macronutrient sensing receptors expressed in enteroendocrine cells and 
the gut peptide(s) they release 
1, 3, 9, 10, 82
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Figure 1: 
Several signals arising from the GI tract are able to regulate energy homeostasis and 
body weight. These comprise GI peptides/hormones, which are secreted by different 
discrete enteroendocrine cell populations distributed along the entire GI tract from 
the stomach to the distal colonic mucosa and include the orexigenic hormone 
ghrelin and anorexigenic hormones (CCK, GLP-1, OXM PYY, nesfatin-1 and leptin); 
intestinal epithelium derived signals, such as ApoA-IV, guanylin and uroguanylin; 
anorexigenic and orexigenic lipid-derived molecules (oleoyethanolamide [OEA] and 
endocannabinoid); and nutrient metabolites produced by gut microbiota (acetate, 
butyrate and propionate). The enteric nervous system (ENS) interacts with the 
autonomic nervous system, EEC products and is able to directly sense absorbed 
nutrients. In turn, the ENS fine-tunes the function of EECs. Vagal afferent firing is 
influenced by a wide-range of gut peptides, gut-derived lipid-mediators, shifts in gut 
microbiota, gut inflammation and leptin. 
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